BACKGROUND: Based on microbiologic concerns, the safety of a 24-month regimen of subantimicrobial dose doxycycline (SDD; 20 mg twice a day) was evaluated in postmenopausal osteopenic women with periodontitis in a double-blind, placebo-controlled, randomized clinical trial. METHODS: Subgingival samples were collected from two sites (probing depth > or = 5 mm) in each of 128 subjects at baseline, with the same sites resampled at the conclusion of the 2-year period. The samples were enumerated on selective and non-selective media and on doxycycline (4 microg/ml) medium. Up to five different colonial morphologies were subcultured from the doxycycline medium, identified to species, and susceptibilities determined to doxycycline and five other antibiotics. Data were analyzed for microbial differences in total colony forming units (CFU), periodontal and opportunistic pathogens, and changes in species and in susceptibilities of isolates recovered on doxycycline medium. RESULTS: There was no significant evidence that changes in total anaerobic counts over the treatment period (P = 0.96) differed between treatment groups. Likewise, periodontal pathogens, opportunistic pathogens, or normal flora did not differ descriptively between groups. Although there was a significant increase (P <0.001) in the total CFU recovered from the 4 microg/ml doxycycline plates at 24 months for SDD versus placebo, the percentage that was clinically resistant to doxycycline (minimal inhibitory concentration [MIC] > or = 16 microg/ml) decreased over the 24-month period in both groups and did not differ between the treatment groups (SDD: 79% to 76%; placebo: 83% to 70%; P = 0.2). There were no significant differences (P >0.28 for each) in the change in cross-resistance between the groups for doxycycline and the other five antibiotics. CONCLUSIONS: No antimicrobial effect on the subgingival flora was detected following treatment with SDD for 24 months, relative to baseline or to placebo. The increase in initial resistance (at 4 microg/ml) did not translate into a significant increase in the percent resistant to doxycycline (MIC > or = 16 microg/ml) for patients in the SDD group.
RCT Entities:
BACKGROUND: Based on microbiologic concerns, the safety of a 24-month regimen of subantimicrobial dose doxycycline (SDD; 20 mg twice a day) was evaluated in postmenopausal osteopenicwomen with periodontitis in a double-blind, placebo-controlled, randomized clinical trial. METHODS: Subgingival samples were collected from two sites (probing depth > or = 5 mm) in each of 128 subjects at baseline, with the same sites resampled at the conclusion of the 2-year period. The samples were enumerated on selective and non-selective media and on doxycycline (4 microg/ml) medium. Up to five different colonial morphologies were subcultured from the doxycycline medium, identified to species, and susceptibilities determined to doxycycline and five other antibiotics. Data were analyzed for microbial differences in total colony forming units (CFU), periodontal and opportunistic pathogens, and changes in species and in susceptibilities of isolates recovered on doxycycline medium. RESULTS: There was no significant evidence that changes in total anaerobic counts over the treatment period (P = 0.96) differed between treatment groups. Likewise, periodontal pathogens, opportunistic pathogens, or normal flora did not differ descriptively between groups. Although there was a significant increase (P <0.001) in the total CFU recovered from the 4 microg/ml doxycycline plates at 24 months for SDD versus placebo, the percentage that was clinically resistant to doxycycline (minimal inhibitory concentration [MIC] > or = 16 microg/ml) decreased over the 24-month period in both groups and did not differ between the treatment groups (SDD: 79% to 76%; placebo: 83% to 70%; P = 0.2). There were no significant differences (P >0.28 for each) in the change in cross-resistance between the groups for doxycycline and the other five antibiotics. CONCLUSIONS: No antimicrobial effect on the subgingival flora was detected following treatment with SDD for 24 months, relative to baseline or to placebo. The increase in initial resistance (at 4 microg/ml) did not translate into a significant increase in the percent resistant to doxycycline (MIC > or = 16 microg/ml) for patients in the SDD group.
Authors: L M Golub; T Sorsa; H M Lee; S Ciancio; D Sorbi; N S Ramamurthy; B Gruber; T Salo; Y T Konttinen Journal: J Clin Periodontol Date: 1995-02 Impact factor: 8.728
Authors: Ted R Mikuls; Jeffrey B Payne; Fang Yu; Geoffrey M Thiele; Richard J Reynolds; Grant W Cannon; Jeffrey Markt; David McGowan; Gail S Kerr; Robert S Redman; Andreas Reimold; Garth Griffiths; Mark Beatty; Shawneen M Gonzalez; Debra A Bergman; Bartlett C Hamilton; Alan R Erickson; Jeremy Sokolove; William H Robinson; Clay Walker; Fatiha Chandad; James R O'Dell Journal: Arthritis Rheumatol Date: 2014-05 Impact factor: 10.995
Authors: Jeffrey B Payne; Lorne M Golub; Julie A Stoner; Hsi-Ming Lee; Richard A Reinhardt; Timo Sorsa; Marvin J Slepian Journal: J Am Dent Assoc Date: 2011-03 Impact factor: 3.634
Authors: Lorne M Golub; Hsi Ming Lee; Julie A Stoner; Timo Sorsa; Richard A Reinhardt; Mark S Wolff; Maria E Ryan; Pirkka V Nummikoski; Jeffrey B Payne Journal: J Periodontol Date: 2008-08 Impact factor: 6.993
Authors: Fellipe A T de Figueiredo; Roberta C Shimano; Edilson Ervolino; Dimitrius L Pitol; Raquel F Gerlach; Joao Paulo M Issa Journal: Sci Rep Date: 2019-10-25 Impact factor: 4.379
Authors: Lorne M Golub; Muna S Elburki; Clay Walker; Maria Ryan; Timo Sorsa; Howard Tenenbaum; Michael Goldberg; Mark Wolff; Ying Gu Journal: Int Dent J Date: 2016-03-23 Impact factor: 2.607